Genotype-Guided Warfarin Dosing
Genotyping to determine CYP2C9, CYP4F2 and VKORC1 genetic variants is considered investigational for managing the administration and dosing of warfarin, including guiding the initial dose to decrease time to stable INR and reduce the risk of serious bleeding. Suggested starting doses are also provided when genotyping information is unavailable, which indicates that genetic testing is not required.